WE Initate Science & Technology Value,
Always for Caring

Media

Company News Popular Science
2022-01-10

Experts From Program for Appropriate Technology in Health (PATH) Visited WestVac Biopharma to Guide Related Work
January 6th to 8th, 2022, Yuan Yuan, head of commerce and business development, GAO Guang, senior technical officer, and DONG Haiyan, senior project officer of Shanghai Representative Office, PATH, visited WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma"), carried out a three-day investigation and training work, and the WestVac Biopharma team accompanied the investigation and held discussion exchange.
Read More
2022-01-06

Progress of WestVac Biopharma's COVID-19 Vaccine Has Attracted International Attention and Reported by Many Overseas Authoritative Media
Recently, the progress of the second generation COVID-19 vaccine of WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma") has attracted international media attention, and has been reported by The Associated Press, Asahi Shinbun, Fox News, Agencia EFE and other overseas authoritative media, causing widespread concern in the global society. In just a few days, more than 600 reports were published.
Read More
2021-12-31

To Boost the High-quality Development of Chengdu, WestVac Biopharma Accelerates the Pace of Scientific＆Technological Innovation
In recent years, Chengdu has focused on the construction of the biopharmaceutical track, accelerated and drove the landing and development of a number of high level projects, and promoted the listing of numerous biopharmaceutical companies on the capital market, which has achieved excellent performance and significant development, and boosted high-quality development of Chengdu by allowing more financial resources to be channeled into the real economy.
Read More
2021-12-20

COVID-19 Vaccine Developed by WestVac BioPharma Has Achieved A Significant Progress Against Omicron
In virtue of funding from the national emergency response project for the mutant COVID-19 vaccine, WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain.
Read More
2021-12-03

Characteristics of Insect Cell Baculovirus Expression Vector System
Insect cell baculovirus expression vector system (IC-BEVS) is one of the four major expression systems (insect cell, bacterial, yeast and mammalian cell expression systems).
Read More
2021-12-02

WestVac Biopharma has begun to develop a recombinant protein vaccine against Omicron strain
On November 29, in response to the newly emerging COVID-19 variant strain - Omicron, Wei Yuquan, academician of the Chinese Academy of Sciences and chairman of WestVac Biopharma Co.
Read More
2021-11-30

Foundation for Biomedical Research and Innovation at Kobe (FBRI) - SEAKNIT Biotechnology Co., Ltd. Arrived at WestVac Biopharma to Visit and Exchange
On November 29, 2021, Foundation for Biomedical Research and Innovation at Kobe (FBRI) - Chairman LIU Miaomiao of SEAKNIT Biotechnology Co., Ltd.
Read More
2021-11-16

WestVac Biopharma and the Coalition for Epidemic Preparedness Innovations (CEPI) Held a Video Conference on R＆D Progress of the COVID-19 Vaccine
On November 16, 2021, WestVac BioPharma Co., Ltd. and experts from The Coalition for Epidemic Preparedness Innovations (CEPI) held a video conference on R＆D progress of the WestVac Biopharma’s COVID-19 vaccine.
Read More
2021-11-07

ZENG Guang: A Most Powerful Vaccine Combination is Required in China to Form an Immunologic Barrier
On November 6, at the 4th Hongqiao International Health Technology Innovation Forum, the official event of the 4th China International Import Expo (CIIE),
Read More
2021-10-21

Vice Minister ZHANG Yudong of MOST Visited WestVac
In the afternoon of October 20th 2021, ZHANG Yudong, Vice Minister of Science and Technology, LIU Dong,
Read More
2021-10-20

China Life Science and Biotech Development Report 2021 Released in Chengdu
On October 20th, 2021 China Biotech Innovation Conference, a national grand event in biotechnology, was officially opened in Chengdu, Sichuan. Nearly 30 academicians, over 300 leading experts, 1,000 scholars, and representatives of about 20 Fortune 500 multinational pharmaceutical companies and more than 50 well-known domestic and foreign pharmaceutical enterprises gathered in Chengdu to discuss the new development of biotechnology in China.
Read More
2021-10-05

Many Experts Were Invited by WestVac Biopharma to Carry Out GMP Training
From October 3 to 5, 2021, the GMP training conference of Chengdu WestVac BioPharma Co., Ltd. was held in Bio-town, Chengdu.
Read More
2021-09-09

WHO Expert Was Invited by WestVac Biopharma to Visit＆Guide Related Work
From September 7 to 8, 2021, Dr. TANG Yi, an official of the WHO Representative Office in China, was invited by WestVac BioPharma Co., Ltd.
Read More
2021-08-31

The First time in China! The Recombinant COVID-19 Vaccine developed by WestVac and West China Hospital of Sichuan University enters clinical trials in Japan
In August 2021, the Recombinant COVID-19 Vaccine (Sf9 Cell) developed by WestVac Biopharma Co.,Ltd and National Key Laboratory of Biotherapy, West China Hospital of Sichuan University entered clinical trials in Japan.
Read More
2021-07-21

Deputy Commissioner CHEN Shifei of NMPA Visited WestVAc
On the morning of July 21st 2021, CHEN Shifei, Deputy Commissioner of the National Medical Products Administration, HE Xun, Deputy Director-General of Sichuan Medical Products Administration and YU Hui,
Read More
2021-07-18

Academician Wei’s Team Receives WCHSCU Innovation Translational Prize 2021 for Covid-19 Vaccine Phase III Clinical Trial Achievements
On July 18, 2021, West China Hospital of Sichuan University (“WCHSCU”), put into operation at its heartland a translational medicine (TM) complex as TM research infrastructure and a key clinical research facility of provincial and national importance. On the ceremony
Read More
2021-02-25

Shanghai Pharmaceutical etc has invested in westvac, the vaccine R&D and production and immunotherapy cpmmpany
On ​February 25, Westvac had an industrial and commercial change, adding Shanghai Pharmaceutical(601607.SH), Chengdu Yike Investment Management Co., Ltd. and other shareholders. At the same time, the company’s registered capital increased from 10 million yuan to 790 million yuan, an increase of 7800%, according to the data from Tianyancha APP.
Read More
2020-11-25

The total investment of this cooperation exceeded 5.1 billion! Chengdu High-Tech Industrial Development Zone, Shanghai Pharmaceutical and Westvac Biopharma singed cooperation agreements in the research and development of COVID-19 vaccines.
On November 25, the signing ceremony of the cooperation agreement between Chengdu High-Tech Industrial Development Zone, Shanghai Pharmaceutical and Westvac Biopharma(here in after referred to as “Westvac”) was held in Shanghai. The total investment of this cooperation exceeded 5.1 billion yuan.
Read More
2020-11-16

Li Gang,  vice governor of Sichuan Province Government, attended and witnessed the westvac/west china hospital's COVID-19 vaccine R&D entered phase II of clinical trial & westvac company's a-round financing signing ceremony
On November 16, Li Gang, vice governor of Sichuan Province Government, attended and witnessed the signing ceremony.
Read More
2020-11-16

Nearly 300 million yuan securing in round of a financing of westvac for vaccine research and development
On November 16, the investment signing ceremony between Westvac Biopharma, Sichuan Development and Shanghai Pharmaceutical, was held in Chengdu Xiangyu Hotel. Li Weimin, Dean of West China Hospital of Sichuan University, presided over the Westvac signing ceremony.
Read More
2020-08-22

China's first recombinant protein COVID-19 vaccine production line produced by insect cells landed in ChengDu, planning to produce hundreds of millions vaccine per year

On August 22, the Red Star News reporter was informed that the recombinant protein COVID-19 vaccine developed by National Key Laboratory of Biotherapy of West China Hospital of Sichuan University was approved by the State Food and Drug Administration for clinical trials.
Read More
2020-07-20

Westvas has completed nearly 300 million yuan in round a financing & the production base is expected to be completed by the end of the year

Recently, WestVac Biopharma(here in after referred to as Westvac) announced that it has completed A-round of financing of nearly 300 million yuan, led by Sichuan Development, Shanghai Pharmaceutical, West China Hospital and the team of scientists Funding for scientific and technological achievements, this round of financing was mainly used for production line construction and clinical research development.
Read More